Dermatomyositis and polymyositis (myositis) trials in United Kingdom

In United Kingdom 9 Also abroad 124

9 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study of AZD0120 in Autoimmune Diseases
Where
Edinburgh, London
Age
18 years to 75 years
People
27 worldwide
Run by
AstraZeneca
See details and how to joinNCT07295847
Phase 3Not yet taking people in United Kingdom
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Where
Birmingham, Bristol, Doncaster, Edinburgh, Harrow, Liverpool, Salford, Wolverhampton
Age
18 years and over
People
270 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Glasgow, London, Southampton
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Where
Liverpool, London, Salford
Age
18 years and over
People
240 worldwide
Run by
argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00
Phase 2/3Taking people
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Where
London, Manchester, Salford
Age
6 years to 75 years
People
74 worldwide
Run by
Cabaletta Bio
See details and how to joinNCT06154252 · EU 2025-521145-24-01
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Edinburgh, London, Wolverhampton
Age
18 years to 75 years
People
240 worldwide
Run by
AstraZeneca
See details and how to joinNCT06455449
Phase 3Taking people
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Where
Doncaster, Glasgow, Salford
Age
18 years and over
People
318 worldwide
Run by
Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00
Phase 1Taking people
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Where
Cambridge, London, Manchester
Age
12 years to 70 years
People
244 worldwide
Run by
Fate Therapeutics
See details and how to joinNCT06308978
No phaseNot yet taking people in United Kingdom
IBM Dietary Surveillance Study
Where
Manchester
Age
40 years and over
People
47
Run by
Manchester Metropolitan University
See details and how to joinNCT07535996